Blog
About

39
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Poster: found
      Is Open Access

      LOW-MOLECULAR-WEIGHT-HEPARIN AS PROPHYLAXIS FOR ORTHOPEDIC COVID-19 PATIENTS: OFF-LABEL FOR DOSAGE OR INDICATION FOR INCREASED RISK?

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In COVID-19, thromboembolic complications represent one of the most relevant signs associated with mortality. It has been proposed the use of LMWH in therapeutic dosage therefore off-label. Between March and April 2020, sixteen patients with COVID-19 were admitted to our structure for major non-deferrable orthopedic surgery. The first series of patients received prophylactic treatment of 4000 UI/die of LMWH, while the second series of 9 patients were treated with 4000 IU/twice a day. The data collected and published so far indicate that LMWH has a favorable benefit/risk ratio with efficacy in the prophylaxis of thromboembolic phenomena in COVID-19 patients undergoing orthopedic surgery, greater than any adverse events. The reduction of associated disseminated thromboembolic phenomena with the escalated dose of LMWH does not represent the cure for COVID-19 but could favor survival. It will be necessary to collect further data on the off-label use of LMWH in this patient setting to legitimize a request for extension of indication to the regulatory authorities.

          Related collections

          Author and article information

          Journal
          ScienceOpen Posters
          ScienceOpen
          27 November 2020
          Affiliations
          [1 ] IRCCS Orthopedic Institute Galeazzi
          Article
          10.14293/S2199-1006.1.SOR-.PPBF81V.v1

          This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

          Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

          Cardiovascular Medicine, Anesthesiology & Pain management, Pharmacology & Pharmaceutical medicine, Infectious disease & Microbiology

          Blood coagulation, COVID-19, Venous Thromboembolism, Heparin

          Comments

          Comment on this article